Nonvisualization of the Endolymphatic Duct, Sac Common in Meniere Disease
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 5, 2023 -- Nonvisualization of the endolymphatic duct (ED) and sac (ES) system is significantly associated with Meniere disease (MD), according to a study published online Aug. 31 in Frontiers in Neurology.
Lisa M.H. de Pont, from Haga Teaching Hospital in the Hague, Netherlands, and colleagues investigated whether nonvisualization of the ED-ES system is a discriminative radiological feature for MD and whether different angular trajectories of the ED-ES system in MD are associated with distinguishable clinical features. The analysis included 301 patients (187 definite MD and 114 other vertigo-associated pathologies) who underwent four-hour-delayed three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging.
The researchers found that nonvisualization of the ED-ES system was more common in definite MD patients versus other vertigo-associated pathologies. The MD-140 subtype showed a longer history of vertigo, a higher prevalence of bilateral clinical disease, and a trend toward a male preponderance among definite MD patients. There were no significant differences observed between angular trajectory of the vestibular aqueduct subgroups and the presence or severity of auditory symptoms or the frequency of vertigo attacks.
"Prospective studies are needed to further investigate the radiological appearance of the ED-ES system in correlation with cochleovestibular symptoms and other clinical parameters, which could have a significant impact on our understanding of the disease, as well as the diagnosis and counseling of MD patients," the authors write.
One author disclosed grants from Oticon and Advances Bionics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.